Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development

Catalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development Catalent, the leader in enabling the development and supply of…

Read MoreCatalent Adds New Cryogenic Capabilities at Shiga, Japan, Facility to Support Clinical Supply Demand for Cell and Gene Therapy Development

Bolivia conducts a simulation exercise to strengthen the National Deployment and Vaccination Plan for influenza and other respiratory viruses

Bolivia conducts a simulation exercise to strengthen the National Deployment and Vaccination Plan for influenza and other respiratory viruses As part of a series of twelve workshops to identify lessons…

Read MoreBolivia conducts a simulation exercise to strengthen the National Deployment and Vaccination Plan for influenza and other respiratory viruses

Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD)

Ultomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD) Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5…

Read MoreUltomiris approved in Japan for the prevention of relapses in patients with neuromyelitis optica spectrum disorder (NMOSD)

Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy

Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in…

Read MoreImfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival in advanced endometrial cancer when added to chemotherapy